International Journal of Endocrinology最新文献

{"title":"Association between Intrapancreatic Fat Deposition and Lower High-Density Lipoprotein Cholesterol in Individuals with Newly Diagnosed T2DM.","authors":"Jianliang Wang,&nbsp;Qingyun Cai,&nbsp;Xiaojuan Wu,&nbsp;Jiaxuan Wang,&nbsp;Xiaona Chang,&nbsp;Xiaoyu Ding,&nbsp;Jia Liu,&nbsp;Guang Wang","doi":"10.1155/2023/6991633","DOIUrl":"https://doi.org/10.1155/2023/6991633","url":null,"abstract":"<p><strong>Background: </strong>Intrapancreatic fat deposition (IPFD) usually occurs in individuals with type 2 diabetes mellitus (T2DM), but its physiopathological influence remains controversial. The present study aimed to investigate IPFD and its associations with various aspects of glucose and lipid metabolism in individuals with newly diagnosed T2DM.</p><p><strong>Methods: </strong>A total of 100 individuals were included, consisting of 80 patients with newly diagnosed T2DM and 20 age- and sex-matched healthy controls. Then, we assessed IPFD using magnetic resonance imaging (MRI) and various parameters of glucose and lipid metabolism.</p><p><strong>Results: </strong>Individuals with newly diagnosed T2DM had a significantly higher IPFD (median: 12.34%; IQR, 9.19-16.60%) compared with healthy controls (median: 6.35%; IQR, 5.12-8.96%) (<i>p</i> < 0.001). In individuals with newly diagnosed T2DM, IPFD was significantly associated with FINS and HOMA-IR in unadjusted model (<i>β</i> = 0.239, <i>p</i>=0.022; <i>β</i> = 0.578, <i>p</i>=0.007, respectively) and adjusted model for age and sex (<i>β</i> = 0.241, <i>p</i>=0.022; <i>β</i> = 0.535, <i>p</i>=0.014, respectively), but these associations vanished after adjustment for age, sex, and BMI. The OR of lower HDL-C for the prevalence of high IPFD was 4.22 (95% CI, 1.41 to 12.69; <i>p</i>=0.010) after adjustment for age, sex, BMI, and HbA1c.</p><p><strong>Conclusions: </strong>Lower HDL-C was an independent predictor for a high degree of IPFD.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10660544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composite Dietary Antioxidant Index Is Negatively Associated with Hyperuricemia in US Adults: An Analysis of NHANES 2007-2018.","authors":"Zhenzong Lin,&nbsp;Haokai Chen,&nbsp;Qiwen Lan,&nbsp;Yinghan Chen,&nbsp;Wanzhe Liao,&nbsp;Xuguang Guo","doi":"10.1155/2023/6680229","DOIUrl":"https://doi.org/10.1155/2023/6680229","url":null,"abstract":"<p><p>Hyperuricemia and its complications are severe risks to human health. Dietary intervention is considered an essential part of the management of hyperuricemia. Studies have reported that the intake of antioxidants has a positive effect on hyperuricemia. Here, we collected data from 8761 participants of the National Health and Nutrition Examination Survey for this analysis. Daily intakes of vitamins A, C, and E; manganese; selenium; and zinc were calculated as the composite dietary antioxidant index (CDAI). The participants were divided into four groups (Q1, Q2, Q3, and Q4) according to the CDAI. Univariate analysis was used to assess the association of covariates with hyperuricemia. The association between the CDAI and hyperuricemia was evaluated using multinomial logistic regression, and its stability was determined by stratified analysis. Our results revealed that the CDAI has a significant negative association with hyperuricemia (Q2: 0.81 (0.69, 0.95); Q3: 0.75 (0.62, 0.90); Q4: 0.65 (0.51, 0.82); <i>P</i> < 0.01). The results of stratified analysis emphasize that this association between CDAI and hyperuricemia is stable. In conclusion, this study suggested a negative association between the CDAI and hyperuricemia.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10106340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunocytochemistry Profile of Benign Thyroid Nodules Not Responding to Thermal Ablation: A Retrospective Study.","authors":"Stella Bernardi,&nbsp;Silvia Taccogna,&nbsp;Martina D'Angelo,&nbsp;Fabiola Giudici,&nbsp;Giovanni Mauri,&nbsp;Bruno Raggiunti,&nbsp;Doris Tina,&nbsp;Fabrizio Zanconati,&nbsp;Enrico Papini,&nbsp;Roberto Negro","doi":"10.1155/2023/7951942","DOIUrl":"https://doi.org/10.1155/2023/7951942","url":null,"abstract":"<p><strong>Purpose: </strong>Thermal ablations (TA) are gaining ground as alternative options to conventional therapies for symptomatic benign thyroid nodules. Little is known about the impact of nodule biology on the outcomes of TA. The aim of our study was to evaluate the baseline immunocytochemistry profile of thyroid nodules that were poorly responsive to TA in order to identify potential predictors of the treatment response.</p><p><strong>Methods: </strong>From a cohort of 406 patients with benign thyroid nodules treated with TA and followed for 5 years, we retrospectively selected two groups of patients: NONRESPONDERS (patients who did not respond to TA and were later surgically treated) and RESPONDERS (patients who responded to TA). The fine-needle aspiration cytology (FNAC) slides obtained before TA were stained for Galectin-3, HBME-1, CK-19, and Ki-67.</p><p><strong>Results: </strong>Benign nodules of NONRESPONDERS (<i>n</i> = 19) did not express CK-19 (<i>p</i> = 0.03), as compared to RESPONDERS (<i>n</i> = 26). We combined the absence of CK-19 and the presence of Ki-67 to obtain a composite biomarker of resistance to TA, which discriminated between likelihood of retreatment and no retreatment with an AUC of 0.68 (95%CI: 0.55-0.81) and a sensitivity, specificity, PPV, and NPV of 29%, 91%, 71%, and 64%, respectively.</p><p><strong>Conclusion: </strong>In benign thyroid nodules, the absence of CK-19 was associated with resistance to TA, while the presence of CK-19 was predictive of response to TA. If confirmed, this finding could provide rapid and inexpensive information about the potential outcome of TA on benign thyroid nodules. In addition, as CK-19 can be expressed in adenomatous hyperplasia, it could be speculated that these nodules, rather than follicular adenomas, might be better candidates for TA.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Uric Acid to High Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Nonoverweight/Obese Patients with Type 2 Diabetes.","authors":"Yuliang Cui,&nbsp;Zhenzhen Qu,&nbsp;Wenmei Hu,&nbsp;Haiyan Shi","doi":"10.1155/2023/2513175","DOIUrl":"https://doi.org/10.1155/2023/2513175","url":null,"abstract":"<p><strong>Aims: </strong>To investigate the relationship between uric acid to high-density lipoprotein cholesterol ratio (UHR) levels and nonalcoholic fatty liver disease (NAFLD) in nonoverweight/obese patients with type 2 diabetes.</p><p><strong>Methods: </strong>A retrospective study was designed including a total of 343 inpatients with type 2 diabetes whose BMI<24 kg/m². The population was divided into three groups as the UHR tertiles. Logistic regression analysis was performed to estimate odds ratios (ORs) of UHR for NAFLD. ROC curve analysis was used to estimate the diagnostic value of UHR for NAFLD.</p><p><strong>Results: </strong>The prevalence rat of NAFLD enhanced progressively from the tertile 1 to tertile 3 of UHR (30.70% vs. 56.52% vs. 73.68%). Logistic regression analysis showed that participants in the higher UHR groups, compared with those in the first tertile group, had higher occurrence risks for NAFLD. The positive association between UHR and NAFLD was independent of age, BMI, blood pressure, hepatic enzymes, and other components of metabolic disorders. ROC curve analysis showed that the area under curve (AUC), sensitivity, and specificity for UHR were 0.697, 0.761, and 0.553, respectively.</p><p><strong>Conclusions: </strong>In type 2 diabetic patients without overweight or obesity, UHR is significantly associated with NAFLD and can be used as a novel and useful predictor for NAFLD onset.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10326412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 18 Months of Growth Hormone Replacement Therapy on Bone Mineral Density in Patients with Adult Growth Hormone Deficiency: A Retrospective Study.","authors":"Ya-Yin Shen,&nbsp;Jia-Ni Ma,&nbsp;Zi-Yu Ren,&nbsp;Jie Liu,&nbsp;Xin-Yi Zhou,&nbsp;Xue-Rui Xie,&nbsp;Wei Ren","doi":"10.1155/2023/4988473","DOIUrl":"https://doi.org/10.1155/2023/4988473","url":null,"abstract":"<p><strong>Objective: </strong>The effect of physiological dose growth hormone (GH) replacement therapy on bone mineral density (BMD) in adults with growth hormone deficiency (GHD) is not well defined. We aimed to investigate the effects of 18 months of treatment with recombinant human growth hormone (rhGH) at physiological doses on BMD, body composition (BC), and quality of life (QoL).</p><p><strong>Methods: </strong>Sixty-eight patients diagnosed with adult growth hormone deficiency (AGHD) in our hospital were included in this retrospective study. All patients received individualized rhGH replacement to maintain normal serum insulin-like growth factor-1 (IGF-1) levels. BMD and BC measurements were performed by dual energy X-ray absorptiometry (DXA). Excluding those with incomplete follow-up data, we analyzed BMD in 68 patients, as well as BC and QoL in 36 of them.</p><p><strong>Results: </strong>Compared with the baseline, lumbar spine BMD decreased by 0.008 g/cm² (<i>P</i>=0.006) and increased by 0.011 g/cm² (<i>P</i>=0.045) at month 18, and total hip BMD decreased by 0.005 g/cm² (<i>P</i>=0.008) and did not change significantly from the baseline at month 18. The changes in BMD did not differ by sex, and the increase in BMD was more pronounced in patients with low <i>Z</i>-scores at the baseline (lumbar spine: <i>P</i>=0.005 and total hip: <i>P</i>=0.018). The percentage change from the baseline in BMD was greater for the lumbar spine than for the total hip (<i>P</i>=0.003). Lean body mass (LBM) increased significantly (<i>P</i>=0.012), total body fat ratio (TBF%) decreased significantly (<i>P</i>=0.011), visceral adipose tissue (VAT) decreased significantly (<i>P</i>=0.016), and QoL improved significantly (<i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Within 18 months of treatment, bone resorption manifested first, BMD decreased to a nadir at month 6, and then it increased. The increase in BMD was greater in the lumbar spine than in the hip, and the increase was more pronounced in patients with low BMD. Eighteen months of rhGH replacement therapy significantly improved lumbar spine BMD and improved BC and QoL.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of IGF-1 Level with Low Bone Mass in Young Patients with Cushing's Disease.","authors":"Wanwan Sun,&nbsp;Quanya Sun,&nbsp;Qiaoli Cui,&nbsp;Min He,&nbsp;Wei Wu,&nbsp;Yiming Li,&nbsp;Hongying Ye,&nbsp;Shuo Zhang","doi":"10.1155/2023/3334982","DOIUrl":"https://doi.org/10.1155/2023/3334982","url":null,"abstract":"<p><strong>Purpose: </strong>Few related factors of low bone mass in Cushing's disease (CD) have been identified so far, and relevant sufficient powered studies in CD patients are rare. On account of the scarcity of data, we performed a well-powered study to identify related factors associated with low bone mass in young CD patients.</p><p><strong>Methods: </strong>This retrospective study included 153 CD patients (33 males and 120 females, under the age of 50 for men and premenopausal women). Bone mineral density (BMD) of the left hip and lumbar spine was measured by dual energy X-ray absorptiometry (DEXA). In this study, low bone mass was defined when the Z score was -2.0 or lower.</p><p><strong>Results: </strong>Among those CD patients, low bone mass occurred in 74 patients (48.37%). Compared to patients with normal BMD, those patients with low bone mass had a higher level of serum cortisol at midnight (22.31 (17.95-29.62) vs. 17.80 (13.75-22.77), <i>p</i>=0.0006), testosterone in women (2.10 (1.33-2.89) vs. 1.54 (0.97-2.05), <i>p</i>=0.0012), higher portion of male (32.43% vs. 11.54%, <i>p</i>=0.0016) as well as hypertension (76.12% vs. 51.67%, <i>p</i>=0.0075), and lower IGF-1 index (0.59 (0.43-0.76) vs. 0.79 (0.60-1.02), <i>p</i>=0.0001). The Z score was positively associated with the IGF-1 index in both the lumbar spine (<i>r</i> = 0.35153, <i>p</i> < 0.0001) and the femoral neck (<i>r</i> = 0.24418, <i>p</i>=0.0057). The Z score in the femoral neck was negatively associated with osteocalcin (<i>r</i> = -0.22744, <i>p</i>=0.0229). Compared to the lowest tertile of the IGF-1 index (<0.5563), the patients with the highest tertile of the IGF-1 index (≥0.7993) had a lower prevalence of low bone mass (95% CI 0.02 (0.001-0.50), <i>p</i>=0.0002), even after adjusting for confounders such as age, gender, duration, BMI, hypertension, serum cortisol at midnight, PTH, and osteocalcin.</p><p><strong>Conclusions: </strong>The higher IGF-1 index was independently associated with lower prevalence of low bone mass in young CD patients, and IGF-1 might play an important role in the pathogenesis of CD-caused low bone mass.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9871941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with Hypocortisolism Treated with Continuous Subcutaneous Hydrocortisone Infusion (CSHI): An Option for Poorly Controlled Patients.","authors":"Malene Lyder Mortensen,&nbsp;Marie Juul Ornstrup,&nbsp;Claus H Gravholt","doi":"10.1155/2023/5315059","DOIUrl":"https://doi.org/10.1155/2023/5315059","url":null,"abstract":"<p><strong>Objective: </strong>Despite appropriate oral glucocorticoid replacement therapy, patients with hypocortisolism often suffer from impaired health and frequent hospitalizations. Continuous subcutaneous hydrocortisone infusion (CSHI) has been developed as an attempt to improve the health status of these patients. The objective of this study was to compare the effects of CSHI to conventional oral treatment on hospitalizations, glucocorticoid doses, and subjective health status. <i>Patients</i>. Nine Danish patients (males: 4 and females: 5) with adrenal insufficiency (AI) were included, with a median age of 48 years, due to Addison (<i>n</i> = 4), congenital adrenal hyperplasia (<i>n</i> = 1), steroid induced secondary adrenal insufficiency (<i>n</i> = 2), morphine induced secondary adrenal insufficiency (<i>n</i> = 1), and Sheehan's syndrome (<i>n</i> = 1). Only patients with severe symptoms of cortisol deficit on oral treatment were selected for CSHI. Their usual oral hydrocortisone doses varied from 25-80 mg per day. The duration of follow-up depended on when the treatment was changed. The first patient started CSHI in 2009 and the last in 2021.</p><p><strong>Design: </strong>A retrospective case series comparing hospitalizations and glucocorticoid doses before and after treatment with CSHI. In addition, patients were retrospectively interviewed about their health-related quality of life (HRQoL) after the change of treatment modality.</p><p><strong>Results: </strong>Patients significantly reduced their daily dose of glucocorticoids by 16.1 mg (<i>p</i> = 0.02) after changing to CSHI. The number of hospital admission due to adrenal crisis decreased by 1.3 per year on CSHI, which was a 50% reduction (<i>p</i> = 0.04). All patients found it easier to handle an adrenal crisis with CSHI, and almost all patients found it easier to overcome everyday activities and had fewer symptoms of cortisol deficit such as abdominal pain and nausea (7-8 out of 9 patients).</p><p><strong>Conclusions: </strong>The change of treatment from conventional oral hydrocortisone to CSHI resulted in a reduced daily dose of glucocorticoids and a reduced number of hospitalizations. Patients reported regain of energy, achievement of better disease control, and better handling of adrenal crisis.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CS27109, A Selective Thyroid Hormone Receptor-<i>β</i> Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models.","authors":"Shengjian Huang,&nbsp;Zhou Deng,&nbsp;Wei Wang,&nbsp;Guoqiang Liao,&nbsp;Yiru Zhao,&nbsp;Hua Zhong,&nbsp;Qian Zhang,&nbsp;Jing Liu,&nbsp;Xuhua Mao,&nbsp;Beizhong Chen,&nbsp;Desi Pan,&nbsp;You Zhou","doi":"10.1155/2023/4950597","DOIUrl":"https://doi.org/10.1155/2023/4950597","url":null,"abstract":"<p><strong>Background/aim: </strong>Thyroid hormone receptor-<i>β</i> (THR-<i>β</i>) agonists play crucial roles in dyslipidemia and metabolic associated fatty liver disease (MAFLD). We developed a novel oral and liver-targeted THR-<i>β</i> agonist, CS27109, and evaluated its efficacy in the treatment of metabolic disorders.</p><p><strong>Materials and methods: </strong>We evaluated <i>in vitro</i> and <i>in vivo</i> efficacy and/or safety of CS27109 along with MGL3196 (a phase III THR-<i>β</i> agonist).</p><p><strong>Results: </strong>CS27109 showed pronounced activity and selectivity to THR-<i>β</i> and favorable PK properties, which was equivalent to MGL3196. In the hamster model, animals treated with a high dose of CS27109 showed equivalent reductions in serum TC and LDL-c with groups treated with MGL3196. In the rat model, CS27109 and MGL3196 reduced serum ALT, TC, TG, LDL-c, liver weight ratio, and liver steatosis. CS27109 simultaneously decreased liver TG and TC, and MGL3196 additionally reduced AST. In the mouse model, CS27109 dose-dependently reduced serum AST, ALT, liver inflammation, and NAS score, and also downregulated TC, LDL-c, liver steatosis, and fibrosis, but not in a dose-dependent manner. MGL3196 revealed an equivalent effect with CS27109 in that model. CS27109 also exhibited tolerable toxicity to the heart.</p><p><strong>Conclusions: </strong>CS27109 shows comparative <i>in vitro</i> and <i>in vivo</i> efficacy with MGL3196, suggesting its potential therapeutic application in the treatment of MAFLD such as dyslipidemia and steatohepatitis.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10778829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Opinion on the Diagnosis and Management of Male Hypogonadism in India.","authors":"Sanjay Kalra,&nbsp;Jubbin Jacob,&nbsp;A G Unnikrishnan,&nbsp;Ganapathi Bantwal,&nbsp;Abhay Sahoo,&nbsp;Rakesh Sahay,&nbsp;Sushil Jindal,&nbsp;Madhu Sudan Agrawal,&nbsp;Nitin Kapoor,&nbsp;Banshi Saboo,&nbsp;Mangesh Tiwaskar,&nbsp;Kapil Kochhar","doi":"10.1155/2023/4408697","DOIUrl":"https://doi.org/10.1155/2023/4408697","url":null,"abstract":"<p><p>Male hypogonadism (MH) is a clinical and biochemical syndrome caused by inadequate synthesis of testosterone. Untreated MH can result in long-term effects, including metabolic, musculoskeletal, mood-related, and reproductive dysfunction. Among Indian men above 40 years of age, the prevalence of MH is 20%-29%. Among men with type 2 diabetes mellitus, 20.7% are found to have hypogonadism. However, due to suboptimal patient-physician communication, MH remains heavily underdiagnosed. For patients with confirmed hypogonadism (either primary or secondary testicular failure), testosterone replacement therapy (TRT) is recommended. Although various formulations exist, optimal TRT remains a considerable challenge as patients often need individually tailored therapeutic strategies. Other challenges include the absence of standardized guidelines on MH for the Indian population, inadequate physician education on MH diagnosis and referral to endocrinologists, and a lack of patient awareness of the long-term effects of MH in relation to comorbidities. Five nationwide advisory board meetings were convened to garner expert opinions on diagnosis, investigations, and available treatment options for MH, as well as the need for a person-centered approach. Experts' opinions have been formulated into a consensus document with the aim of improving the screening, diagnosis, and therapy of men living with hypogonadism.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Risk Factors and Development of a Predictive Model for Postoperative Hypoglycemia among Diabetic Patients during the Perioperative Period.","authors":"Zixuan Liu,&nbsp;Jing Dai,&nbsp;Xiaodie He,&nbsp;Jiaxi Li,&nbsp;Haixia Zhang,&nbsp;Cheng Ji","doi":"10.1155/2023/8033101","DOIUrl":"https://doi.org/10.1155/2023/8033101","url":null,"abstract":"<p><strong>Objective: </strong>To explore the incidence and influencing factors of postoperative hypoglycemia in diabetic patients during the perioperative period and to construct a risk prediction model for postoperative hypoglycemia.</p><p><strong>Methods: </strong>Patients with T2DM admitted to the nonendocrinology department of Nanjing Drum Tower Hospital from December 2019 to January 2022 were included as research subjects. Basic information, hospital blood glucose management methods, laboratory indicators, and surgery-related indicators were collected. A risk prediction model and scoring table for postoperative hypoglycemia in patients with perioperative diabetes mellitus were established.</p><p><strong>Results: </strong>A total of 440 patients were included, of which 109 had hypoglycemia, resulting in an incidence of postoperative hypoglycemia of 24.78%. The results show that preoperative C-peptide and operation duration were risk factors for postoperative hypoglycemia, while BMI and preoperative fasting blood glucose were protective factors.</p><p><strong>Conclusion: </strong>The model constructed in this study is a good method for evaluating the risk of postoperative hypoglycemia. The scoring table intuitively quantifies the risk of risk factors for outcome variables and has strong clinical practicability.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}